Emerald Mutual Fund Advisers Trust Has $26.99 Million Stock Holdings in Insmed, Inc. (NASDAQ:INSM)

Emerald Mutual Fund Advisers Trust decreased its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 11.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 353,831 shares of the biopharmaceutical company's stock after selling 46,793 shares during the period. Insmed makes up 1.9% of Emerald Mutual Fund Advisers Trust's holdings, making the stock its 6th largest position. Emerald Mutual Fund Advisers Trust owned 0.19% of Insmed worth $26,994,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in INSM. OneDigital Investment Advisors LLC increased its position in shares of Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock valued at $399,000 after buying an additional 1,673 shares in the last quarter. Sowell Financial Services LLC bought a new position in Insmed during the 1st quarter worth about $255,000. GAMMA Investing LLC increased its holdings in Insmed by 62.0% during the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 386 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Insmed by 16.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock worth $288,000 after purchasing an additional 541 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its holdings in Insmed by 37.7% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 19,935 shares of the biopharmaceutical company's stock worth $1,521,000 after purchasing an additional 5,453 shares in the last quarter.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of Insmed stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares of the company's stock, valued at $8,352,401.94. This trade represents a 52.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 1,879 shares of Insmed stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $73.50, for a total transaction of $138,106.50. Following the transaction, the insider owned 67,718 shares of the company's stock, valued at $4,977,273. The trade was a 2.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 539,686 shares of company stock worth $48,257,890. 3.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on INSM. UBS Group lowered their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Bank of America increased their price objective on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. The Goldman Sachs Group increased their price objective on shares of Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Royal Bank Of Canada increased their price objective on shares of Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 11th. Finally, Citigroup upgraded shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $108.07.

Insmed Stock Performance

Shares of INSM stock traded up $0.98 during trading on Tuesday, reaching $102.87. 3,953,124 shares of the company's stock traded hands, compared to its average volume of 2,294,742. The company has a market capitalization of $19.52 billion, a P/E ratio of -17.29 and a beta of 0.90. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The firm's 50-day moving average is $83.40 and its 200 day moving average is $77.44. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. Insmed's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.06) EPS. Equities research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.